12.21  0.38 (3.21%)		01-09 16:00
Open: 11.915 High: 12.5 Volume: 1,098,285		Pre. Close: 11.83 Low: 11.89 Market Cap: 1,015(M)

Short term
Mid term
Targets	6-month :	15.7	1-year :	17.59
Resists	First :	13.44	Second :	15.06
Pivot price	12
Supports	First :	10.82	Second :	9.01
MAs	MA(5) :	11.76	MA(20) :	12.14
	MA(100) :	12.75	MA(250) :	8.13
MACD	MACD :	-0.5	Signal :	-0.5
%K %D	K(14,3) :	58.6	D(3) :	44.5
RSI	RSI(14): 46.7
52-week	High :	16.95	Low :	2.59

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AMLX ] has closed below upper band by 35.6%. Bollinger Bands are 52% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	12.51 - 12.6	12.6 - 12.67
Low:	11.67 - 11.76	11.76 - 11.83
Close:	12.09 - 12.23	12.23 - 12.34

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Thu, 08 Jan 2026
Top Amylyx Executives Quietly Cash Out in Coordinated Stock Moves - TipRanks

Thu, 08 Jan 2026
Mizuho reiterates Outperform rating on Amylyx stock, cites GLP-1 program - Investing.com

Thu, 08 Jan 2026
Amylyx Pharmaceuticals, Inc. Announces Development of AMX0318 - TradingView — Track All Markets

Thu, 08 Jan 2026
Long-acting GLP-1 antagonist named for rare post-bariatric hypoglycemia - Stock Titan

Mon, 05 Jan 2026
Assessing Amylyx Pharmaceuticals (AMLX) Valuation After Insider Buying And AMX0114 Trial Progress - Sahm

Sun, 04 Jan 2026
Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase and Clinical Data - Quiver Quantitative

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	110 (M)
Held by Insiders	7.492e+007 (%)
Held by Institutions	7.4 (%)
Shares Short	11,910 (K)
Shares Short P.Month	0 (K)

EPS	-1.9297e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	29 %
Return on Assets (ttm)	104.2 %
Return on Equity (ttm)	-39.5 %
Qtrly Rev. Growth	-665000 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-1.8 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-154 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-1.33

Dividend	0
Forward Dividend	1.207e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.